Report cover image

Global CD19-targeted CAR-T Cell Therapy Market Growth (Status and Outlook) 2026-2032

Publisher LP Information, Inc.
Published Jan 14, 2026
Length 100 Pages
SKU # LPI20716185

Description

The global CD19-targeted CAR-T Cell Therapy market size is predicted to grow from US$ 3508 million in 2025 to US$ 9852 million in 2032; it is expected to grow at a CAGR of 16.2% from 2026 to 2032.

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. Currently available CAR-T cell therapy products are divided into CD19 targets and BCMA targets. CD19 is the most common target. CD19 is a protein that is found on the surface of most B - cells, including malignant B - cells in certain types of leukemia and lymphoma.

United States market for CD19-targeted CAR-T Cell Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for CD19-targeted CAR-T Cell Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for CD19-targeted CAR-T Cell Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key CD19-targeted CAR-T Cell Therapy players cover Gilead (Yescarta&Tecartus), Novartis (Kymriah), Bristol-Myers Squibb (Breyanzi), FOSUNKite (Yescarta), Shanghai Yaoming Juno (Carteyva), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the “CD19-targeted CAR-T Cell Therapy Industry Forecast” looks at past sales and reviews total world CD19-targeted CAR-T Cell Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected CD19-targeted CAR-T Cell Therapy sales for 2026 through 2032. With CD19-targeted CAR-T Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CD19-targeted CAR-T Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global CD19-targeted CAR-T Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CD19-targeted CAR-T Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CD19-targeted CAR-T Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD19-targeted CAR-T Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CD19-targeted CAR-T Cell Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of CD19-targeted CAR-T Cell Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Yescarta
Kymriah
Tecartus
Others

Segmentation by Application:
Lymphoma
Lymphocytic Leukemia

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gilead (Yescarta&Tecartus)
Novartis (Kymriah)
Bristol-Myers Squibb (Breyanzi)
FOSUNKite (Yescarta)
Shanghai Yaoming Juno (Carteyva)
Juventas

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

100 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 CD19-targeted CAR-T Cell Therapy Market Size by Player
4 CD19-targeted CAR-T Cell Therapy by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global CD19-targeted CAR-T Cell Therapy Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us